Foresight Williams Technology led the oversubscribed round alongside several regional and specialist investors.
"We are excited to announce our support for such a forward thinking and innovative business. Nebu~Flow’s development of delivery mechanisms tailored to specific drugs represents an opportunity to expand the market and improve patient outcomes. Foresight Williams Technology’s expertise will offer significant value as the Company develops its products, and we look forward to working with the team at Nebu~Flow during the next stage of their growth."
Quaestus Capital Management led the Series A round to support international growth and sustainable ad technology.
"At the heart of our industry is an inherent value exchange between advertiser and consumer, and I’m on a mission to harness that value as a significant force for good. Through our respectful, positive ad platform, brands can treat people online as partners, rather than targets, united by a desire to have a meaningful social impact. Backing from industry experts like QCM and First Party Capital, social impact investors and, indeed, the general public, will help to supercharge our growth whilst keeping us true to our values at every step along the way."
TRICAPITAL led the investment round with backing from a syndicate of Scottish investors.
"Our next phase of growth will involve building international partnerships, growing the team, and appointing a scientific advisory committee to support the work of the main board."
The syndicate included Mark Bamforth, Tern Plc, SIS Ventures, and Scottish Enterprise.
"2022 promises to be a big year for Talking Medicines with this new investment. Having scaled up our operations and formally launched our PatientMetrx® technology platform, we’ve now got our sights set on expanding in the US pharma market, providing brand teams and agencies with a new way of understanding what patients are really saying and feeling about their medicines. The pharmaceutical industry will go through seismic change this year and our actionable patient insights will be transformational for the industry. Our new office in New Jersey provides the ideal base for us to build relationships with customers, acquire new leads and drive revenue growth."
The investment round was led by Quaestus Capital Management and will support international expansion and carbon reduction technology.
"At the heart of our industry is an inherent value exchange between advertiser and consumer, and I’m on a mission to harness that value as a significant force for good. Through our respectful, positive ad platform, brands can treat people online as partners — rather than targets — united by a desire to have a meaningful social impact. Backing from industry experts like QCM and FirstPartyCapital, social impact investors and, indeed, the general public, will help to supercharge our growth whilst keeping us true to our values at every step along the way."
